Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raffles Medical GroupRAFLF 57 EV-to-EBIT is 15.09 as of Aug. 10, 2026, which is 26% below its 10-year median of 20.53. GuruFocus rates RAFLF with a GF Score™ of 57/100 and a GF Value™ of $0.81 (Fairly Valued). The stock has 5 warning signs investors should review. Among 472 Healthcare Providers & Services companies, Raffles Medical Group ranks better than 52.75% on this metric.
The historical rank and industry rank for Raffles Medical Group's EV-to-EBIT or its related term are showing as below:
RAFLF'
s EV-to-EBIT Range Over the Past 10 Years
Min: 9.17 Med: 20.53 Max: 32.14
Current: 15.02
During the past 13 years, the highest EV-to-EBIT of Raffles Medical Group was 32.14. The lowest was 9.17. And the median was 20.53.
RAFLF's EV-to-EBIT is ranked better than 52.75% of 472
companies
in the Healthcare Providers & Services industry
Industry Median: 15.835
vs RAFLF: 15.02
Raffles Medical Group (OTCPK:RAFLF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Raffles Medical Group's Enterprise Value for the quarter that ended in Jun. 2026 was $1,206.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Raffles Medical Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $71.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Raffles Medical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raffles Medical Group EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raffles Medical Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Raffles Medical Group's EV-to-EBIT falls into.
Raffles Medical Group's current Enterprise Value is $1,075.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Raffles Medical Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $71.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raffles Medical Group (RAFLF) has a EV-to-EBIT of 15.09 as of Aug. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Raffles Medical Group and its competitors. This is 26% below median its historical median of 20.53. Over the past decade, Raffles Medical Group's EV-to-EBIT has ranged from 9.17 to 32.14. According to the industry distribution chart, Raffles Medical Group ranks #223 out of 472 companies in the Healthcare Providers & Services industry, placing it in the top 47.2%.
Is Raffles Medical Group's EV-to-EBIT too high?
Raffles Medical Group's current EV-to-EBIT of 15.09 is 26% below median its 10-year median of 20.53. Over the past 10 years, this metric has ranged from a low of 9.17 to a high of 32.14. The Healthcare Providers & Services industry median EV-to-EBIT is 15.84. Raffles Medical Group's value of 15.09 is 4.7% below this industry median. Based on the distribution chart, Raffles Medical Group ranks #223 out of 472 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Raffles Medical Group has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Raffles Medical Group's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Raffles Medical Group ranks #223 out of 472 companies for EV-to-EBIT. This puts Raffles Medical Group in the upper half of its industry. The industry median EV-to-EBIT is 15.84. Raffles Medical Group's value of 15.09 is 4.7% below this benchmark. Historically, Raffles Medical Group's own EV-to-EBIT has ranged from 9.17 to 32.14 over the past decade. While the company's 10-year median is 20.53 vs. the industry median of 15.84, Raffles Medical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.84, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raffles Medical Group's current EV-to-EBIT of 15.09 is 4.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Raffles Medical Group and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raffles Medical Group's current EV-to-EBIT is 15.09, which is 26% below median its own 10-year median of 20.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raffles Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Raffles Medical Group (RAFLF) is currently considered Fairly Valued. The stock's GF Value™ is $0.81, compared to a current price of $0.75 — trading 7% below its estimated fair value. The current EV-to-EBIT is 15.09, which is 26% below median its 10-year median of 20.53 and 4.7% below the Healthcare Providers & Services industry median of 15.84. Raffles Medical Group's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Raffles Medical Group (RAFLF), the current EV-to-EBIT is 15.09 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raffles Medical Group (RAFLF) Overvalued in 2026?
Based on GuruFocus' analysis, Raffles Medical Group stock appears to be undervalued.
The current stock price of $0.75 is trading 7% below its estimated GF Value™ of $0.81.
GuruFocus considers Raffles Medical Group to be Fairly Valued.
Key valuation signals for RAFLF:
EV-to-EBIT: 15.09 (26% below median its 10-year median of 20.53)
GF Value™: $0.81 vs. price of $0.75 (7% below fair value)
Industry Position: 4.7% below the Healthcare Providers & Services median (#223 of 472)
No single metric tells the full story. See the RAFLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raffles Medical Group Ltd is an integrated private healthcare provider in Asia with operations in Singapore, China, Japan, Vietnam, and Cambodia. The company owns and operates a tertiary hospital, a network of medical and dental clinics, insurance services, Japanese and Traditional Chinese Medicine clinics, and a consumer healthcare division. The company's operating segment includes Healthcare services, Hospital Services, Investment Holdings, and Insurance Services. The company generates revenue from contracts with customers, Rental Income, and Insurance revenue. Geographically operates in Singapore, Greater China, Vietnam, Cambodia and Japan.
57GF Score
Get the complete analysis for RAFLF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAFLF has been successfully added to your 
